• 10,258 core tests sold globally in H1 FY26, up 113% vs PCP
• Annualised run rate surpassed 21,300 tests, on track for 24,000+ for FY26
• Microbiome Explorer increased from 20% to 55% of total revenue vs PCP

The first half of FY26 delivered strong continued growth of Microba's core testing products, reaching an annualised run rate of over 21,300 tests and tracking towards the company's FY26 guidance of 24,000+ core tests. The company sold over 10,000 core tests in the half, more than doubling the prior corresponding period. H1 FY26 revenue was $7.32 million, down 9% on the prior corresponding period, reflecting the planned roll-off of discontinued legacy product revenue. Core testing revenue grew 123% versus PCP, with Growth product revenue reaching $4.0 million, up 135% versus PCP. The company completed the discontinuation of all legacy testing products and services, enabling 100% focus on its core Growth testing products. Microbiome Explorer now represents 55% of total revenue, up from 20% in the prior corresponding period. Microba continued to see record growth in Microbiome Explorer test sales in Australia, with adoption advancing into the early adopter segment. In the UK, adoption is outperforming Australia by 33% at the equivalent time post launch. The company remains intensively focused on executing its commercial growth strategy, advancing towards regional break-even in FY26, and capturing the significant opportunity ahead in this major new diagnostic category.

Microba is tracking towards its FY26 guidance of 24,000+ core tests, aligned to regional break-even objectives for both Australia and the United Kingdom.